NIHR CRN High Level Objectives Year End Performance Report /18

Transcription

1 NIHR CRN High Level Objectives Year End Performance Report /18 Public version: Version July 2018 Delivering research to make patients, and the NHS, better

2 Preface Scope of NIHR HLOs Annual Performance Summary Report This document is produced by the CRN Coordinating Centre (CRNCC), which is responsible for collating and publishing performance data for the NIHR CRN as a whole. The (HLOs) are the Network s national, overarching objectives for research delivery in the NHS; these are defined in Table 1. The HLOs form one element of the suite of performance indicators which are used to assess the Network s performance. Performance against the other elements of the Network s Performance Framework (Clinical Research Network Specialty Objectives, LCRN Operating Framework Indicators and Satisfaction Survey Indicators) will be reported on an annual basis to the Department of Health. This document sets out the NIHR Clinical Research Network s (NIHR CRN) annual performance against its High Level Objectives (HLOs) for the period 1 April 2017 to 31 March 2018, and includes a refreshed data set for Quarter 3 (1 October to 31 December 2017), Quarter 2 (1 July to 30 September 2017) and Quarter 1 (1 April to 30 June 2017). Performance is summarised in Table 1. The information presented represents the most complete information available at the time of publication. The main source of annual performance information is through the Central Portfolio Management System (CPMS). The data presented in this document may be quoted in presentations and papers. However, we ask that the title and issue date of the report are used, to avoid any confusion about the period to which the figures relate and the time at which the data were reported. Red/Amber/Green (RAG) ratings The RAG thresholds used throughout this section are: Red: less than 90% of the performance target Amber: 90% or more of the performance target but less than 100% of the performance target Green: 100% or more of the performance target For the purposes of performance reporting decimal places are rounded up or down to the nearest whole number. 1

3 Further information For feedback on, or queries relating to, the information contained in this document, please contact: Amber O Malley, Head of Performance Management CRN Coordinating Centre Amber.O Malley@nihr.ac.uk Telephone:

4 Table 1. NIHR CRN HLO definitions 2017/18 Objective Measure Target 1 Increase the number of participants recruited into NIHR CRN Portfolio studies Number of participants recruited into NIHR CRN Portfolio studies 650,000 2 Increase the proportion of studies in the NIHR CRN Portfolio delivering to recruitment target and time 3 Increase the number of commercial contract studies delivered through the NIHR CRN 4 Reduce the time taken for eligible studies to achieve set up in the NHS 5 Reduce the time taken to recruit first participant into NIHR CRN Portfolio studies 6 Increase NHS participation in NIHR CRN Portfolio Studies A: Proportion of commercial contract studies achieving or surpassing their recruitment target during their planned recruitment period, at confirmed Network sites B: Proportion of non-commercial studies achieving or surpassing their recruitment target during their planned recruitment period A: Number of new commercial contract studies entering the NIHR CRN Portfolio B: Number of new commercial contract studies entering the NIHR CRN Portfolio as a percentage of the total commercial MHRA CTA approvals for Phase II IV studies Proportion of eligible studies achieving NHS set up at all sites within 40 calendar days (from Date Site Selected to Date Site Confirmed ) A: Proportion of commercial contract studies achieving first participant recruited within 30 days at confirmed Network sites (from Date Site Confirmed to Date First Participant Recruited ) B: Proportion of non-commercial contract studies achieving first participant recruited within 30 days at confirmed Network sites (from Date Site Confirmed to Date First Participant Recruited ) A: Proportion of NHS Trusts recruiting each year into NIHR CRN Portfolio studies B: Proportion of NHS Trusts recruiting each year into NIHR CRN Portfolio commercial contract studies % 99% 70% 3

5 7 Increase the number of participants recruited into Dementias and Neurodegeneration (DeNDRoN) studies on the NIHR CRN Portfolio C: Proportion of General Medical Practices recruiting each year into NIHR CRN Portfolio studies Number of participants recruited into Dementias and Neurodegeneration (DeNDRoN) studies on the NIHR CRN Portfolio 40% 22,500 4

6 Table 2. High Level Objectives Performance Summary Data for 2017/18 (1 April March 2018) [1] 2017/18 performance data is refreshed on a quarterly basis, therefore data will change on a quarterly basis until the annual data cut. This refresh allows the CRN to have a more accurate predictor of year to date performance. [2] Objectives 4, 5a and 5b were revised for 2016/17 in light of the introduction of HRA Approval, replacing NIHR CSP. Previous performance from 2015/16 is not comparable and is therefore not included. [3] This is a cumulative annual measure which increases on a quarterly basis towards the annual target of 40%. 5

7 Performance Analysis HLO 1 725,333 participants were recruited into clinical research studies during 2017/18. This is the best performance to date, 12% higher than the target and 9% above last year s performance. The NIHR CRN Portfolio of studies continues to grow steadily with 2,070 new studies entered on the Portfolio, 5,804 studies open and 4,901 studies actively recruiting. HLO 1 performance is heavily influenced by a small number of high-recruiting studies (6 studies contributed 11% of recruitment (80,355) and 23 studies contributed to over 25% (187,746) of the total). One study was a significant contributor to the large increase in commercial recruits (Study ID: Short title: EPI FLU VS UK). HLO 2A 74% of commercial contract studies achieved recruitment to time and target. This is the highest percentage to date and continues the upward trend of the last four years, albeit a more modest improvement than reported last year. There have been no studies excluded due to data quality issues since 2014/15 which demonstrates the effectiveness of business processes. - There is a focus on particular Specialties that require further improvement and plans are in place to improve their performance to further develop this upward trend for overall performance. HLO 2B of non-commercial studies achieved recruitment to time and target, achieving the target for the second consecutive year. The volume of studies increased by 10% in 2017/18, 1,078 studies contributed to HLO 2B maintaining high performance whilst supporting more studies than ever. - There is a focus on particular Specialties that require further improvement and plans are in place to improve their performance to further develop this upward trend for overall performance. HLO 3A 697 new commercial contract studies were added to the NIHR CRN Portfolio, surpassing the target, and just 32 fewer studies than 2016/17. HLO 3B The number of new commercial contract studies entering the NIHR CRN Portfolio as a percentage of the total commercial MHRA CTA approvals for Phase II-IV studies was 79%, surpassing the target for the sixth year running. HLO 4 66% of eligible studies achieved NHS set up at all sites within 40 calendar days in 2017/18 compared to 60% in 2016/17, while the numbers of studies has increased significantly (1437, compared to 583 last year). NIHR CRN Portfolio study level data completeness is 99.7% (of 1,441 possible studies, 1,437 reported startup activities) and Trust level completeness has improved (median 93%, with a minimum of 75% 6

8 in CRN West of England and a maximum of 99% in CRN South London) /18 utilises data points that are now aligned with the NIHR 70 benchmark. There is ongoing activity across NHS England, NIHR and HRA under the proposals for simplifying research arrangements that is specifically exploring cross-system approaches to streamline data collection and key performance indicators for a true representation of start-up timelines. HLO 5A 35% of commercial contract studies achieved first participant recruited within 30 days at confirmed Network sites in 2017/18. There are issues around the consistency of measurement and data entry making it difficult to draw conclusions about performance. These are being addressed through the ongoing activity across NHS England, NIHR and HRA. - Increased data is now available for studies undergoing HRA approval. This metric is difficult to determine minimum values for, but using CPMS recruitment to determine when first participant should have been recorded gives a completion rate of 83% (266 of 322 studies). HLO 5B 49% of non-commercial studies achieved first participant recruited within 30 calendar days at confirmed Network sites in 2017/18. In 2017/18 performance was measured for 834 studies, compared to 239 in 201 6/17. However ongoing issues with the central and local portfolio management system capture of this data is reflected in the lack of data available for the studies within this measure. HLO 6A 99% of NHS Trusts recruited into NIHR CRN Portfolio studies, achieving the target. All acute trusts have recruited every year since the HLOs were agreed with only two Community Healthcare Trusts which were not research active. We are working with them to assess future opportunities. HLO 6B 82% of NHS Trusts recruited to commercial contract studies, surpassing the target of 70% (193 of 234 trusts have recruited to commercial studies), c ontinuing the upward trend in performance since 2015/16. HLO 6C 32% of General Medical Practices recruited one or more participants into NIHR CRN Portfolio studies in 2017/18. Performance was lower than 2016/17, largely due to the closure of the TIME study which recruited from over 1800 Practices. HLO 7 33,208 participants were recruited into Dementias and Neurodegeneration (DeNDRoN) Specialty studies and the annual performance is well above target (22,500 participants) for the fourth year running. - Three studies contributed 29% of total annual recruitment. - The pipeline of new DeNDRoN studies remains stable, between 81 and 88 studies in each of the last five years. 7

9 21 Queen Street Leeds LS1 2TW Tel: Web: